Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomarker research 2021-05, Vol.9 (1), p.30-30, Article 30
Hauptverfasser: Zhang, Xiang, Qian, Jiejing, Wang, Huafeng, Wang, Yungui, Zhang, Yi, Qian, Pengxu, Lou, Yinjun, Jin, Jie, Zhu, Honghu
Format: Artikel
Sprache:eng
Schlagworte:
Acquired resistance
Acute myeloid leukemia
Analysis
Cancer therapies
Chemotherapy
Chronic lymphocytic leukemia
Drug dosages
Hematology
Laboratories
Letter to the Editor
Leukemia
Lymphatic leukemia
Medical diagnosis
Medical research
Medicine, Experimental
Mutation
Myeloid leukemia
Remission
Tumor proteins
Venetoclax
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is
ISSN:2050-7771
2050-7771
DOI:10.1186/s40364-021-00288-7